Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians’ Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 2.0 Contact Hours.

Acknowledgment of Commercial Support

This activity is supported by educational grants from AstraZeneca; Athenex; Daiichi Sankyo, Inc.; Foundation Medicine, Inc.; Genomic Health, Inc.; Merck & Co., Inc.; and Seattle Genetics, Inc.

Enduring CME Activity: School of Breast Oncology® Live Video Webcast: Clinical Updates from San Antonio

Release Date: January 30, 2020
Expiration Date: January 30, 2021
Media: Internet - based

Activity Overview

This online activity is the enduring program from the School of Breast Oncology® Live Video Webcast: Clinical Updates from San Antonio program of a live-streamed, interactive webcast featuring leading experts in the field of breast cancer who will provide a comprehensive overview of noteworthy data presented at the international society meeting held in San Antonio in December of 2019. In this enduring activity, the expert panel will discuss and debate the clinical implications and applications of these data and the future direction of breast cancer management. This program is an extension of the annual School of Breast Oncology®, and it provides an additional forum for clinicians to keep pace with rapidly emerging data and advancing treatment paradigms in breast cancer.

The enduring activity offers education to augment your foundation of knowledge and clinical competence in several areas, including:

  • Integrating predictive and/or prognostic molecular markers and genomic assays to individualize treatment selection for patients with breast cancer
  • Evolving paradigms in (neo)adjuvant therapy for HR+, HER2+, and triple-negative breast cancers
  • Clinical insights regarding endocrine, cytotoxic, targeted, and immunotherapeutic agents for the treatment of metastatic breast cancer, including current treatment options and emerging agents
  • Trends, challenges, and controversies in the locoregional management of early stage and locally advanced breast cancers

The format of this live online broadcast is an in-studio panel discussion where experts present highlights of key data, followed by discussion and debate about key concepts and clinical applications in breast cancer.

Acknowledgement of Commercial Support

This activity is supported by educational grants from AstraZeneca; Athenex; Daiichi Sankyo, Inc.; Foundation Medicine, Inc.; Genomic Health, Inc.; Merck & Co., Inc.; and Seattle Genetics, Inc.

Instructions for This Activity and Receiving Credit

  • You will need to log in to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review video files/content until you finish the presentation.
  • At the end of the activity, “Educational Content/Videos” will be available for your reference.
  • In order to receive a CME/CE Certificate, you must complete the activity.
  • Complete the Posttest and the Evaluation, and then click on “Request for Credit.” You may immediately download a CME/CE Certificate upon completion of these steps.

Target Audience

This activity is directed toward medical oncologists who treat patients with breast cancer. Fellows, nurses, nurse practitioners, physician assistants, and other healthcare professionals involved in the management of breast cancer are also invited to participate.

Learning Objectives

Upon successful completion of this educational activity, you should be better prepared to:

  • Discuss the study design and primary endpoints of recently reported and ongoing clinical trials evaluating novel strategies for the management of breast cancer
  • Compare and contrast the safety and efficacy profiles of novel therapeutic strategies that impact breast cancer management
  • Integrate emerging evidence into treatment paradigms across the breast cancer disease subtype and stage continuum

Faculty, Staff, and Planners’ Disclosures

Chair:

Joyce O’Shaughnessy
Joyce O’Shaughnessy, MD
Celebrating Women Chair in Breast Cancer Research
Baylor University Medical Center
Texas Oncology
Co-Chair of the Breast Cancer Research Program
The US Oncology Network
Dallas, TX

Disclosures: Honoraria for consulting and advisory boards: AbbVie Inc, Agendia, Amgen Biotechnology, AstraZeneca, Bristol-Myers Squibb, Celgene Corporation, Eisai, Genentech, Genomic Health, GRAIL, Immunomedics, Heron Therapeutics, Ipsen Biopharmaceuticals, Jounce Therapeutics, Lilly, Merck, Myriad, Novartis, Ondonate Therapeutics, Pfizer, Puma Biotechnology, Prime Oncology, Roche, Seattle Genetics, Syndax Pharmaceuticals, Takeda.

Faculty:

David M. Euhus
David M. Euhus, MD, FACS
Professor of Surgery and Chief of the Breast Surgery Section
Division of Surgical Oncology
John Hopkins Medicine
Baltimore, MD

Disclosures: no relevant financial relationships with commercial interests to disclose.

Joseph A. Sparano
Joseph A. Sparano, MD
Professor, Department of Medicine (Oncology)
Professor, Department of Obstetrics, Gynecology, and Women's Health
Associate Chairman for Clinical Research, Department of Oncology
Montefiore Medical Center
Associate Director for Clinical Research
Albert Einstein Cancer Center
Bronx, NY

Disclosures: Grant/Research Support: Deciphera, Prescient Therapeutics, Radius. Consultant: Epic Sciences, Astra Zeneca, Roche, Eli Lilly, Celgene, Pfizer.

Tiffany A. Traina
Tiffany A. Traina, MD
Clinical Director, Breast Medicine Service
Section Head, Triple Negative Breast Cancer Clinical Research Program
Memorial Sloan Kettering Cancer Center
Associate Professor
Weill Cornell Medical College
New York, NY

Disclosures: Grant/Research Support: Eisai, Pfizer, Novartis, Innocrin Pharma, AstraZeneca, Astellas Pharma, Immunomedics, Genentech/Roche, Daiichi Sankyo. Consultant: Genentech, Medivation, Pfizer, AstraZeneca, Merck, Astellas Pharma, Puma Biotechnology, Advaxis, Celgene, Innocrin Pharma, Genomic Health, Bristol- Myers Squibb, Samsung, Athenex, Aduro Biotech, Halozyme. Speakers Bureau: Roche/Genentech.

The staff of Physicians' Education Resource®, LLC (PER®) have no relevant financial relationships with commercial interests to disclose.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME/CE activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME/CE activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.

Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This CME/CE activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME/CE activity is for continuing medical and nursing education purposes only and is not meant to substitute for the independent clinical judgment of a physician and nurse relative to diagnostic or treatment options for a specific patient’s medical condition.

The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or the company that provided commercial support.


Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
SUNMONTUESWEDTHURSFRISAT
      1
2345678
9101112131415
16171819202122
23242526272829
Filter By